Notícias e Atividades da Clal Biotechnology Industries

A Clal Biotechnology Industries pertence à AAR Consortium. AAR Consortium tem presença direta em 17 países.

AAR Consortium possui 50 subsidiárias incluindo ABH Holdings, Access Industries e ADA Worldwide.

Eles estão dentro:

• Música31%
• Mídia14%
• Outro55%

Veja o organograma con seus 9 executivos principais

Biografias mais buscadas da Clal Biotechnology Industries

• Avi Fischer, Chairman of the Board and Chief Executive Officer
• Nufar Malovani, Director
• Gabi Barabash, Director

Criar um alerta
para seguir os movimentos de executivos da Clal Biotechnology Industries.

AAR Consortium possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).
• SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Clal Biotechnology Industries

• אסיפת בעלי מניות 31.10.2024 14:00 – CBI
• MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma | MediWound
• MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers | MediWound
• Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 – Investors – Gamida Cell Ltd.
• BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization | BioLineRx
• BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer | BioLineRx
• BioLineRx Announces Preliminary Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer | BioLineRx
• BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer | BioLineRx
• BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition | BioLineRx
• Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in Non-Alcoholic Steatohepatitis (NASH)
• View more press releases Close

Redes sociais sobre Clal Biotechnology Industries

• Clal Biotechnology Industries na Wikipedia, Google News e Yahoo Finance
• Clal Biotechnology Industries na LinkedIn, Twitter e YouTube